阿德福韦酯(代丁)治疗71例慢性乙型肝炎疗效观察  

Clinical Effectiveness of Adefovir Dipivoxil for 71 Patients with Chronic Hepatitis B

作　　者：曹芹芳[1] 阳乔[1] 张曜文[1] 吴文杰[1] 唐望先[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肝病研究所,武汉430030

出　　处：《华中科技大学学报（医学版）》2011年第1期116-118,124,共4页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

摘　　要：目的观察阿德福韦酯治疗慢性乙型肝炎的临床疗效和安全性。方法选取慢性乙型肝炎患者71例,口服国产阿德福韦酯(代丁)10 mg,每日1次,连续服用52周。观察用药12、24、52周患者血清乙型肝炎病毒脱氧核糖核酸(HBV-DNA)、谷丙转氨酶(ALT)、谷草转氨酶(AST)的变化,以及乙型肝炎e抗原(HBeAg)阴转率和乙型肝炎e抗原/乙型肝炎e抗体(HBeAg/anti-HBe)血清转换率。结果患者在治疗12、24、52周时血清HBV-DNA、ALT、AST与治疗前比较均有显著的下降,差异均有统计学意义;52周时患者HBeAg阴转率和血清转换率分别是31.5%和16.7%,ALT恢复至正常的百分比为74.6%。结论阿德福韦酯治疗慢性乙型肝炎的疗效显著,能有效地抑制病毒复制并能改善肝功能,是有效的抗乙型肝炎病毒药物。Objective To evaluate the efficacy and safety of adefovir dipivoxil（ADV）for chronic hepatitis B.Methods Seventy-one patients with chronic hepatitis B were treated with adefovir dipivoxil（10 mg daily）for 52 weeks.Levels of HBV-DNA,ALT,AST,HBeAg loss rate and HBeAg/anti-HBe seroconversion rate were detected at different time points during the treatment.The efficacy was evaluated at 12th,24th,and 52nd week.Results The levels of HBV-DNA,ALT and AST were significantly decreased after treatment for 12,24,52 weeks.At 52nd week,ALT returned to the normal in 74.6% patients.Negative rate of HBeAg was 31.5%,and the seroconversion rate of HBeAg was 16.7%.The efficacy of adefovir dipiroxil showed significant difference before and after treatment.Conclusion Adefovir dipivoxil can effectively inhibit HBV replication,significantly improve liver function in chronic hepatitis B patients,and enhance transformation from HBe-antigen to anti-HBe.It is safe and has a good tolerance.It is effective for both HBeAg positive and HBeAg negative patients.

关 键 词：慢性乙型肝炎 乙型肝炎病毒 阿德福韦酯 

分 类 号：R512.62[医药卫生—内科学]